goetzpartners advised Curetis N.V.

Curetis N.V. (Euronext: CURE) announced on April 27, 2018 that it intends to issue 854,166 new shares to qualified investors at a price of EUR 4.80 per share, raising in total gross proceeds of EUR 4.1 million. The funds are expected to be mostly used for the US market launch and continued commercial roll-out of the Unyvero platform as well as specific R&D projects for expanding the product menu and platform capabilities. The company secured concurrently to the share placement a USD 10 million equity drawdown facility (c. EUR 8.3 million*).
 
The new shares were sold by way of a private placement to qualified investors in the U.S. and Europe in compliance with applicable securities laws. With the completion of the transaction the number of registered shares of Curetis increased to 16,392,577.
 
goetzpartners securities was acting as Sole Placement Agent for Curetis in the offering.
 

ABOUT CURETIS
Curetis N.V. is focused on providing innovative solutions for molecular microbiology diagnostics designed to diagnose severe infectious diseases and identify antibiotic resistances in hospitalized patients. Curetis is located in Holzgerlingen, Germany. The Company is listed on Euronext Amsterdam and Euronext Brussels under ISIN NL0011509294 and ticker symbol CURE. Visit www.curetis.com for additional information on Curetis.
 
* at ECB USD/EUR reference rate of 27 April 2018

Transaction team:

Martin Brunninger
Managing Director

Wolf Dornbusch
Director

Erland Sternby
Marketing Sales

Youchen Xin
Associate